Pharmacologic treatment of orthostatic hypotension

[1]  Jun.  Octreotide , 1989, The Lancet.

[2]  J. Muldowney,et al.  Cardiovascular Safety Considerations in the Treatment of Neurogenic Orthostatic Hypotension. , 2020, The American journal of cardiology.

[3]  E. Benarroch.  Physiology and Pathophysiology of the Autonomic Nervous System. , 2020, Continuum.

[4]  H. Kaufmann,et al.  Orthostatic Hypotension in Parkinson Disease. , 2020, Clinics in geriatric medicine.

[5]  K. Chu,et al.  Efficacy of atomoxetine versus midodrine for neurogenic orthostatic hypotension , 2019, Annals of clinical and translational neurology.

[6]  M. Lobo.  Fludrocortisone , 2019, Reactions Weekly.

[7]  O. Tysnes,et al.  Orthostatic hypotension in Parkinson disease , 2019, Neurology.

[8]  G. Mancia,et al.  Management of supine hypertension in patients with neurogenic orthostatic hypotension: scientific statement of the American Autonomic Society, European Federation of Autonomic Societies, and the European Society of Hypertension. , 2019, Journal of hypertension.

[9]  A. Duhig,et al.  Six‐Month Use of Droxidopa for Neurogenic Orthostatic Hypotension , 2019, Movement disorders clinical practice.

[10]  A. Diedrich,et al.  Synergistic Pressor Effect of Atomoxetine and Pyridostigmine in Patients With Neurogenic Orthostatic Hypotension , 2019, Hypertension.

[11]  J. Muldowney,et al.  Initiation of droxidopa during hospital admission for management of refractory neurogenic orthostatic hypotension in severely ill patients , 2018, bioRxiv.

[12]  G. Mancia,et al.  Consensus statement on the definition of neurogenic supine hypertension in cardiovascular autonomic failure by the American Autonomic Society (AAS) and the European Federation of Autonomic Societies (EFAS) , 2018, Clinical Autonomic Research.

[13]  R. Freeman,et al.  Orthostatic heart rate changes in patients with autonomic failure caused by neurodegenerative synucleinopathies , 2018, Annals of neurology.

[14]  E. Benarroch,et al.  Neuropathology of autonomic dysfunction in synucleinopathies , 2018, Movement disorders : official journal of the Movement Disorder Society.

[15]  L. Hewitt,et al.  Comparison of the Pharmacokinetics of Droxidopa After Dosing in the Fed Versus Fasted State and with 3-Times-Daily Dosing in Healthy Elderly Subjects , 2018, Drugs in R&D.

[16]  A. Tahrani,et al.  Cardiac autonomic neuropathy in patients with diabetes mellitus: current perspectives , 2017, Diabetes, metabolic syndrome and obesity : targets and therapy.

[17]  I. Biaggioni,et al.  Fludrocortisone Is Associated With a Higher Risk of All‐Cause Hospitalizations Compared With Midodrine in Patients With Orthostatic Hypotension , 2017, Journal of the American Heart Association.

[18]  K. Chu,et al.  Efficacy of single or combined midodrine and pyridostigmine in orthostatic hypotension , 2017, Neurology.

[19]  H. Kaufmann,et al.  Integrated analysis of droxidopa trials for neurogenic orthostatic hypotension , 2017, BMC Neurology.

[20]  H. Kaufmann,et al.  Epidemiology, Diagnosis, and Management of Neurogenic Orthostatic Hypotension , 2017, Movement disorders clinical practice.

[21]  D. Waldvogel,et al.  Pyridostigmine bromide versus fludrocortisone in the treatment of orthostatic hypotension in Parkinson's disease – a randomized controlled trial , 2017, European journal of neurology.

[22]  Lixin Guo,et al.  Effectiveness of acarbose in treating elderly patients with diabetes with postprandial hypotension , 2017, Journal of Investigative Medicine.

[23]  R. Freeman,et al.  The recommendations of a consensus panel for the screening, diagnosis, and treatment of neurogenic orthostatic hypotension and associated supine hypertension , 2017, Journal of Neurology.

[24]  I. Biaggioni.  The Pharmacology of Autonomic Failure: From Hypotension to Hypertension , 2017, Pharmacological Reviews.

[25]  R. Freeman,et al.  Diabetic Neuropathy: A Position Statement by the American Diabetes Association , 2016, Diabetes Care.

[26]  Jonathan S. Whitfield,et al.  Efficacy of Servo-Controlled Splanchnic Venous Compression in the Treatment of Orthostatic Hypotension: A Randomized Comparison With Midodrine , 2016, Hypertension.

[27]  A. Lang,et al.  Neurogenic orthostatic hypotension and supine hypertension in Parkinson's disease and related synucleinopathies: prioritisation of treatment targets , 2016, The Lancet Neurology.

[28]  A. Gamboa,et al.  Mineralocorticoid Receptor Activation Contributes to the Supine Hypertension of Autonomic Failure , 2016, Hypertension.

[29]  R. de Caterina,et al.  Cardiovascular morbidity and mortality related to orthostatic hypotension: a meta-analysis of prospective observational studies. , 2015, European heart journal.

[30]  J. Jordan,et al.  Multiple system atrophy: Using clinical pharmacology to reveal pathophysiology , 2015, Clinical Autonomic Research.

[31]  A. Diedrich,et al.  Efficacy of Atomoxetine Versus Midodrine for the Treatment of Orthostatic Hypotension in Autonomic Failure , 2014, Hypertension.

[32]  Leena Choi,et al.  Nebivolol, But Not Metoprolol, Lowers Blood Pressure in Nitric Oxide–Sensitive Human Hypertension , 2014, Hypertension.

[33]  I. Biaggioni.  New Developments in the Management of Neurogenic Orthostatic Hypotension , 2014, Current Cardiology Reports.

[34]  J. Mandrekar,et al.  Midodrine Efficacy in Orthostatic Hypotension , 2014, Journal of General Internal Medicine.

[35]  E. Grouzmann,et al.  Determination of catecholamines in plasma and urine. , 2013, Best practice & research. Clinical endocrinology & metabolism.

[36]  Amy C. Arnold,et al.  Current Concepts in Orthostatic Hypotension Management , 2013, Current Hypertension Reports.

[37]  D. Annane,et al.  Human plasma quantification of fludrocortisone using liquid chromatography coupled with atmospheric pressure chemical ionization mass spectrometry after low-dosage administration. , 2013, Clinica chimica acta; international journal of clinical chemistry.

[38]  A. Gamboa,et al.  Angiotensin II, Independent of Plasma Renin Activity, Contributes to the Hypertension of Autonomic Failure , 2013, Hypertension.

[39]  P. Low,et al.  Autonomic Function Tests: Some Clinical Applications , 2013, Journal of clinical neurology.

[40]  Amy C. Arnold,et al.  Management approaches to hypertension in autonomic failure , 2012, Current opinion in nephrology and hypertension.

[41]  L. Okamoto,et al.  Pharmacotherapy of autonomic failure. , 2012, Pharmacology & therapeutics.

[42]  A. Diedrich,et al.  Sympathetic activation and nitric oxide function in early hypertension. , 2012, American journal of physiology. Heart and circulatory physiology.

[43]  A. Diedrich,et al.  Synergistic Effect of Norepinephrine Transporter Blockade and &agr;-2 Antagonism on Blood Pressure in Autonomic Failure , 2012, Hypertension.

[44]  G. Sobue,et al.  Does cardiovascular autonomic dysfunction contribute to fatigue in Parkinson's disease? , 2011, Movement disorders : official journal of the Movement Disorder Society.

[45]  R. Freeman,et al.  Consensus statement on the definition of orthostatic hypotension, neurally mediated syncope and the postural tachycardia syndrome , 2011, Autonomic Neuroscience.

[46]  A. Diedrich,et al.  Comparative Efficacy of Yohimbine Against Pyridostigmine for the Treatment of Orthostatic Hypotension in Autonomic Failure , 2010, Hypertension.

[47]  A. Gamboa,et al.  Renal Impairment of Pure Autonomic Failure , 2009, Hypertension.

[48]  M. Lamarre-Cliche,et al.  Pharmacokinetic and pharmacodynamic effects of midodrine on blood pressure, the autonomic nervous system, and plasma natriuretic peptides: a prospective, randomized, single-blind, two-period, crossover, placebo-controlled study. , 2008, Clinical therapeutics.

[49]  N. Chaturvedi,et al.  Relationship Between Risk Factors and Mortality in Type 1 Diabetic Patients in Europe , 2008, Diabetes Care.

[50]  D. Robertson,et al.  The pathophysiology and diagnosis of orthostatic hypotension , 2008, Clinical Autonomic Research.

[51]  S. Raj,et al.  Orthostatic hypotension-related hospitalizations in the United States. , 2007, The American journal of medicine.

[52]  T. Pal,et al.  Analysis of Pyridostigmine Bromide in Human Plasma and its Application in Bioequivalence Studies , 2007 .

[53]  A. Diedrich,et al.  Acarbose, an &agr;-Glucosidase Inhibitor, Attenuates Postprandial Hypotension in Autonomic Failure , 2007, Hypertension.

[54]  A. Diedrich,et al.  Norepinephrine Transporter Blockade With Atomoxetine Induces Hypertension in Patients With Impaired Autonomic Function , 2007, Hypertension.

[55]  P. O'Brien,et al.  Pyridostigmine treatment trial in neurogenic orthostatic hypotension. , 2006, Archives of neurology.

[56]  A. Diedrich,et al.  Clonidine for the Treatment of Supine Hypertension and Pressure Natriuresis in Autonomic Failure , 2006, Hypertension.

[57]  P. Sandroni,et al.  Blood pressure recovery from Valsalva maneuver in patients with autonomic failure , 2005, Neurology.

[58]  I. Biaggioni,et al.  Primer on the Autonomic Nervous System: Second Edition , 2004 .

[59]  A. Bharucha,et al.  Acetylcholinesterase inhibition: a novel approach in the treatment of neurogenic orthostatic hypotension , 2003, Journal of neurology, neurosurgery, and psychiatry.

[60]  R. Freeman,et al.  Norepinephrine Precursor Therapy in Neurogenic Orthostatic Hypotension , 2003, Circulation.

[61]  A. Diedrich,et al.  Water drinking as a treatment for orthostatic syndromes. , 2002, The American journal of medicine.

[62]  S. Tam,et al.  Yohimbine: a clinical review. , 2001, Pharmacology & therapeutics.

[63]  S. Tuhrim,et al.  Hypertensive cardiovascular damage in patients with primary autonomic failure , 2000, The Lancet.

[64]  G. Sobue,et al.  Clinical and physiological characteristics of autonomic failure with Parkinson's disease , 1999, Clinical Autonomic Research.

[65]  R. Furlan,et al.  Abnormal norepinephrine clearance and adrenergic receptor sensitivity in idiopathic orthostatic intolerance. , 1999, Circulation.

[66]  P. Low,et al.  A double-blind, dose-response study of midodrine in neurogenic orthostatic hypotension , 1998, Neurology.

[67]  G. Hobbs,et al.  Treatment of orthostatic hypotension with midodrine and octreotide. , 1998, The Journal of clinical endocrinology and metabolism.

[68]  J. Jordan,et al.  The hypertension of autonomic failure and its treatment. , 1997, Hypertension.

[69]  R. Freeman,et al.  Efficacy of midodrine vs placebo in neurogenic orthostatic hypotension. A randomized, double-blind multicenter study. Midodrine Study Group. , 1997, JAMA.

[70]  A. Boulton,et al.  Aromaticl-amino acid decarboxylase: A neglected and misunderstood enzyme , 1996, Neurochemical Research.

[71]  L. Lipsitz,et al.  Postprandial Hypotension: Epidemiology, Pathophysiology, and Clinical Management , 1995, Annals of Internal Medicine.

[72]  W. Wieling,et al.  Treatment of orthostatic hypotension with sleeping in the head‐up tilt position, alone and in combination with fludrocortisone , 1992, Journal of internal medicine.

[73]  C. Mathias.  Effect of food intake on cardiovascular control in patients with impaired autonomic function , 1990, Journal of Neuroscience Methods.

[74]  N. Jowett.  Management of Orthostatic Hypotension , 1987, The Lancet.

[75]  S. Sheps,et al.  Pharmacodynamics of midodrine, an antihypotensive agent , 1986, Clinical pharmacology and therapeutics.

[76]  J. Onrot,et al.  Hemodynamic and humoral effects of caffeine in autonomic failure. Therapeutic implications for postprandial hypotension. , 1985, The New England journal of medicine.

[77]  D. Ewing,et al.  Therapeutic experience with fludrocortisone in diabetic postural hypotension. , 1976, British medical journal.

[78]  R. Hickler,et al.  Successful treatment of orthostatic hypotension with 9-alpha-fluorohydrocortisone. , 1959, The New England journal of medicine.

[79]  P. Kruzliak,et al.  Orthostatic hypotension in diabetic patients-10-year follow-up study. , 2016, Journal of diabetes and its complications.

[80]  G. Plosker,et al.  Atomoxetine , 2012, Drugs.

[81]  M. K. Hahn.  Norepinephrine Transporter Dysfunction , 2004 .

[82]  D. Lyons,et al.  Postprandial hypotension. , 2002, Clinics in geriatric medicine.

[83]  S. Lamberts,et al.  Drug therapy : octreotide , 1996 .

[84]  A. Harris,et al.  Somatostatin and somatostatin analogues: pharmacokinetics and pharmacodynamic effects. , 1994, Gut.

[85]  M. Hoehn.  Levodopa-induced postural hypotension. Treatment with fludrocortisone. , 1975, Archives of neurology.